Paris-based deeptech startup Chipiron has secured €14.9 million in Series A funding to make MRI imaging more accessible, affordable, and widely deployable.
The round was led by Blast, with participation from the EIC Fund, iXcore, and public support from France2030, the EIC Accelerator, and Bpifrance.
Tackling medical imaging’s accessibility gap
Founded in 2020 by Evan Kervella and Dimitri Labat, Chipiron is on a mission to democratise MRI by developing ultra-low-field, compact scanners that can be used in places traditional MRI machines can’t — such as care centres, clinics, and mobile setups. Their devices are easier to install, operate, and maintain, and they’re designed for patients who may be excluded from standard MRI due to implants, discomfort, or mobility issues.
Advertisement
A step toward clinical deployment
The fresh capital will be used to complete product development, build clinical prototypes, and launch hospital-based trials by 2026. Chipiron also plans to expand into the US market, aiming to deploy 100 systems over the next 3–5 years, with the goal of obtaining both FDA and CE approvals.
“This fundraising marks a major turning point,” said CEO Evan Kervella. “Thanks to our investors’ trust, we now have the means to complete R&D and begin clinical investigations.”
A European deeptech success story
The company has now raised over $22 million in total, combining private investment and public support. Previous rounds included backing from Exor Ventures, Unruly Capital, and Entrepreneur First, as well as funding from public innovation programmes between 2021 and 2023.
Backed by investors who believe in scalable diagnostics
“Chipiron is exactly the kind of biotech we want to boost,” said Anthony Bourbon, founder of Blast.Club. “A major public health issue, breakthrough technology, and a strong team.”
Hervé Arditty, President of iXcore, added: “The team is outstanding, the science is solid, and they’re bringing a game-changing product to market.”
The EIC Fund called it “a major technological advancement in a key sector,” underscoring its broader commitment to European deeptech.
Next stop: global transformation in MRI
The company says this funding will be a pivotal moment in bringing its technology to hospitals for real-world testing. According to CSO Dimitri Labat, “This round enables us to install our first device in a hospital and begin acquiring clinical images that will shape the future of medical imaging.”
Chipiron’s long-term aim? To redefine MRI as a universally accessible tool — not a luxury, but a basic building block of modern healthcare.
